ArticleImmunogenetics2022
iTTCA-MFF: identifying tumor T cell antigens based on multiple feature fusion.
Article in Immunogenetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Enhancing tumor T cell antigen prediction by integrating deep protein representations.BMC bioinformatics · 2026Article
- A novel computational framework for tumor-specific T cell antigen identification using a deep neural network.Journal of computer-aided molecular design · 2026Article
- Computational identification of B- and T-cell epitopes: a unified task taxonomy and review of databases, datasets, predictive pipelines, and gaps.Frontiers in immunology · 2026Review
- ENCAP: Computational prediction of tumor T cell antigens with ensemble classifiers and diverse sequence features.PloS one · 2024Article
- StackTTCA: a stacking ensemble learning-based framework for accurate and high-throughput identification of tumor T cell antigens.BMC bioinformatics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a terrible disease, recent studies reported that tumor T cell antigens (TTCAs) may play a promising role in cancer treatment. Since experimental methods are still expensive and time-consuming, it is highly desirable to develop automatic computational methods to identify tumor T cell antigens from the huge amount of natural and synthetic peptides. Hence, in this study, a novel computational model called iTTCA-MFF was proposed to identify TTCAs. In order to describe the sequence effectively, the physicochemical (PC) properties of amino acid and residue pairwise energy content matrix (RECM) were firstly employed to encode peptide sequences. Then, two different approaches including covariance and Pearson's correlation coefficient (PCC) were used to collect discriminative information from PC and RECM matrixes. Next, an effective feature selection approach called the least absolute shrinkage and selection operator (LAASO) was adopted to select the optimal features. These selected optimal features were fed into support vector machine (SVM) for identifying TTCAs. We performed experiments on two different datasets, experimental results indicated that the proposed method is promising and may play a complementary role to the existing methods for identifying TTCAs. The datasets and codes can be available at https://figshare.com/articles/online_resource/iTTCA-MFF/17636120 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.